Clinigen Board Changes

Elmar Schnee appointed as Chairman designate, bringing significant international experience and leadership from the pharmaceutical industry

Ian Johnson to join as independent Non-Executive Director and Senior Independent Director

Clinigen Group plc (AIM: CLIN) ('Clinigen' or the 'Company' or the 'Group'), the global pharmaceutical Products and Services company, announces the appointment of Elmar Schnee as independent Non-Executive Director and Chairman designate and Ian Johnson as a new independent Non-Executive Director and Senior Independent Director. Both appointments are effective from 03 August 2021.

As announced in the Company's trading update on 13 July 2021, Peter Allen, independent Non-Executive Chairman, will not stand for re-election to the Board at the Annual General Meeting (AGM) in November 2021. Peter Allen has served as Chairman since the Group's IPO in September 2012. It is expected that Elmar Schnee will assume the role of Chairman following the AGM in November 2021. Ian Nicholson will also step down at the November AGM. Ian joined the Board in September 2012 and has served as a member of the Nomination and Audit and Risk Committees and chaired the Remuneration Committee. Anne Hyland will step down from her position as Senior Independent Director, but will remain Chair of the Audit and Risk Committee and an independent Non-Executive Director.

Elmar Schnee brings broad experience from the international pharmaceutical industry, having held senior leadership and Board positions across multiple pharmaceutical product and services companies including most recently serving on the Board of Jazz Pharmaceuticals since 2014. Prior to Jazz Pharmaceuticals, and his other Board positions, his career spanned a broad range of senior roles at companies including at Merck KGaA being General Partner and a member of the executive board responsible for the world-wide pharma business and at Merck Serono as CEO and being instrumental in the acquisition of Serono by Merck KGaA, alongside senior global management positions with UCB and Sanofi.

Ian Johnson brings significant experience from the healthcare sector, particularly within the UK listed arena, and he currently serves as Executive Chairman of Circassia Group plc.

Commenting on the Board changes, Shaun Chilton, Chief Executive Officer of Clinigen, said: 

"We are delighted to welcome Elmar and Ian to Clinigen's board. Elmar brings with him a huge amount of knowledge and experience across Services and Products businesses and will provide a fresh approach to the Group governance and leadership. Ian has strong UK plc, and sector, experience that will complement our Board. 

"I would like to thank both Peter Allen and Ian Nicholson for their commitment to Clinigen, having been Chairman and Non-Executive Director, respectively, since the IPO in 2012 and steering the Group through a period of significant growth."

Peter Allen, outgoing Chairman, added: 

"I am pleased to welcome Elmar to the Board as Chairman designate and look forward to working with him until my planned departure in November. I am proud of the achievements including the significant scale up and internationalisation that has made Clinigen into a leading pharma products and services company." 

Incoming Chairman designate, Elmar Schnee, said: 

"I am delighted to be joining Clinigen at a time when the Company is playing a significant role in supplying products and services to its customers and patients around the world. Clinigen's platform has the potential to provide an end to end service to pharmaceutical clients - and this part of the business is yet to demonstrate its full potential. I look forward to working with the Board on the next phase of Clinigen's growth and to unlocking the value enhancing opportunities."

Further background on Elmar Schnee (age 62)

Most recently, Elmar served as a Board member at Jazz Pharmaceuticals from August 2014 until July 2021.  Mr. Schnee currently serves as Chairman of the board of two internationally listed companies and is also a director of several privately-held healthcare companies.

Previously, he served as Chief Operating Officer and management advisor to MindMaze SA, a neuro-technology company, and has also held a number of senior managerial positions within the pharmaceutical industry throughout his career. Mr. Schnee holds both a bachelor's degree in marketing and a master's degree in marketing and general management from the Swiss Institute of Business Administration in Zurich.

Further background on Ian Johnson (age 68)

Ian currently serves as Executive Chairman of Circassia Group and Non-Executive Chairman of Redcentric plc. He has recently announced his intention to step down from Redcentric. Mr. Johnson also served as Executive Chairman of Bioquell PLC and Non-Executive Chairman of Quantum Pharma PLC, Cyprotex PLC and Celsis Group Ltd. Non-Executive Director of Ergomed PLC and on the Boards of AIM listed companies Evans Analytical Group and AOI Medical Inc, amongst other listed companies. Mr. Johnson was a founder and Chief Executive Officer of Biotrace International plc, which was an AIM listed company prior to its sale to 3M in 2006.

Save as disclosed below, in relation to current and past directorships, Clinigen confirms that there are no further disclosures to be made on Elmar Josef Schnee and Ian Roy Johnson in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies:

Elmar Schnee current directorshipsIan Johnson current directorships
  • Santhera AG (public)
  • Calliditas AB (public)
  • Genkyotex SA (public)*

  • Moleac Pte (private)
  • Moleac RX Pte Ltd (private)
  • Noorik AG (private)
  • Damian Pharma AG (private)
  • Kuste Biopharma (private)
  • Mindmaze SA (private)
  • Genpharm (private)
  • GenKyoTex Suisse SA (private)
  • ProCom RX Holding SA (private)
  • MyDIO SA (private - not for profit
  • Circassia Group (public)

  • Circassia Limited (private)

  • Redcentric Plc (public)

Elmar Schnee past directorships (last 5 years)Ian Johnson past directorships (last 5 years
  • Jazz Pharmaceuticals plc
  • Stallergenes-Greer plc
  • Advanz Pharma corp. ltd
  • Anecova SA
  • Bioquell Plc
  • Ergomed Plc
  • Quantum Pharma Plc
  • Cyprotex Plc
  • Celsis Group Ltd
  • Circassia Pharma Ltd
  • Prosonix Ltd

*Mr Schnee will cease to be a director of Genkyotex SA in September 2021

Companies that went into administration (whilst Ian Johnson was a director) and where creditors lost money as a result of liquidation:

Pure Options Solutions - Administrators appointed on 30 November 2010. The estimated deficiency to investors and creditors was £4.49 million.

Toximet Limited - Administrators appointed on 17 November 2015. The estimated deficiency to investors and creditors was £0.83 million.

Contact details

Clinigen Group plc
Shaun Chilton, Chief Executive Officer
Nick Keher, Chief Financial Officer
Rob Fox, VP Investor Relations and Corporate Development
+44 (0) 1283 495010

Numis Securities Limited - Nominated Adviser & Joint Broker
James Black / Garry Levin / Freddie Barnfield
Tel: +44 (0) 20 7260 1000

RBC Capital Markets - Joint Broker
Marcus Jackson / Elliot Thomas
Tel: +44 (0) 20 7653 4000

Consilium Strategic Communications
Mary-Jane Elliott / Matthew Cole / Jessica Hodgson 
Tel: +44 (0) 20 3709 5700

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products platform focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.

Clinigen has more than 1,000 employees across five continents in 16 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 115 countries.

For more information on Clinigen, please visit